Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026.

Corporate Highlights * Announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board * Continued progress on Phase 2/3 clinical study start up activities * Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini